COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy


  • Work carried out at Queen's Veterinary School Hospital, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK.

  • This work was presented at the Veterinary Cancer Society 29th Annual Conference, Texas, October 2009.

Z. Belshaw
School of Veterinary Medicine and Science University of Nottingham Sutton Bonington Campus, near Loughborough Leicestershire LE12 5RD, UK


The expression of cyclooxygenase isoform 2 (COX-2) in canine nasal carcinomas has been well documented. COX-2 expression has proven to be a prognostic factor in several human tumours. The aims of this study were to assess the correlation between immunohistochemical COX-2 expression and prognosis using rhinoscopic biopsies from 42 dogs with nasal carcinomas treated with hypofractionated radiotherapy, and to establish a replicable COX-2 scoring system. Ninety per cent of sections evaluated were COX-2 positive with a mean score of 6.6 (median 8.0; range 0–12). Neither COX-2 expression nor tumour type had a significant correlation with survival. There are likely to be many as yet unidentified variants which contribute to length of survival in dogs with nasal carcinomas. Immunohistochemical COX-2 expression appears unlikely to be of prognostic significance for canine nasal carcinoma.